MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment

BACKGROUND: Programmed death-1 (PD-1) immune checkpoint blockade has achieved clinical successes in cancer therapy. However, the response rate of anti-PD-1 agents remains low. Additionally, a subpopulation of patients developed hyperprogressive disease upon PD-1 blockade therapy. Combination therapy...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Immunother Cancer
Asıl Yazarlar: Fang, Douglas D., Tang, Qiuqiong, Kong, Yanhui, Wang, Qixin, Gu, Jiaxing, Fang, Xu, Zou, Peng, Rong, Tao, Wang, Jingwen, Yang, Dajun, Zhai, Yifan
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2019
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6883539/
https://ncbi.nlm.nih.gov/pubmed/31779710
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0750-6
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller